US2016287563A1PendingUtilityA1
Cysteine Prodrugs
Est. expiryJul 28, 2031(~5 yrs left)· nominal 20-yr term from priority
A61P 31/18A61P 9/00A61P 43/00A61P 25/16A61P 25/28A61P 25/22A61P 25/30A61P 25/24A61P 25/18A61K 31/198A61K 31/426C07D 277/14C07D 241/08A61P 21/02C07D 267/10A61P 25/00A61K 45/06C07K 5/0606
40
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Novel cysteine prodrugs and their use in the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug craving, drug addiction, bipolar disorder, anxiety, depression, Parkinson's disease, Alzheimer's disease, cognitive dysfunction, multiple sclerosis, Amyotrophic lateral sclerosis (ALS), ischemic stroke, HIV dementia, and Huntington's disease.
Claims
exact text as granted — not AI-modified1 . A method of treating a disease or condition of the Central Nervous System (CNS) selected from the group consisting of schizophrenia, drug craving, drug addiction, bipolar disorder, anxiety, depression, Parkinson's disease, Alzheimer's disease, cognitive dysfunction, multiple sclerosis, Amyotrophic lateral sclerosis (ALS), ischemic stroke, HIV dementia, and Huntington's disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the following formula
2 . A method of treating schizophrenia comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the following formula
3 . A method of treating Parkinson's disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the following formulaJoin the waitlist — get patent alerts
Track US2016287563A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.